A Phase 1 interventional study of CD388 Injection and Saline placebo in Healthy, sponsored by Cidara Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by Cidara Therapeutics Inc. (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this first-in-human study is to determine the safety and tolerability profile of CD388 Injection, as compared to saline placebo, when administered as a single dose to healthy adult subjects by injection either in the muscle or under the skin.
A Phase 1, single-center, prospective, randomized, double-blind, single-dose and repeat single-dose, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD388 Injection, as compared to saline placebo, when dosed either by intramuscular (IM) or subcutaneous (SQ) administration to healthy adult subjects.
Cidara Therapeutics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject must meet one of the following criteria:
Normal clinical examination, including:
Exclusion Criteria:
History of any of the following:
Subjects with one or more of the following laboratory abnormalities at screening as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1 (DAIDS 2017):
Note: Retesting of abnormal laboratory values that may lead to exclusion will be allowed once without prior asking approval from the Sponsor. Retesting will take place during a scheduled or unscheduled visit during screening. Subjects with a normal value at retest may be included.
(*) Full COVID-19 vaccination prior to participation is strongly recommended.
(**) In the event a subject chooses to receive one of the two 2-dose approved or emergency-use-authorized COVID 19 vaccines (Comirnaty® [Pfizer], Spikevax™ [Moderna]) in the interval between two CRU stays (Cohort 2A/2B or Cohort 3A/3B), flexibility in timing of the second CRU stay should be applied, to allow appropriate receipt of the second vaccine dosage or booster (based on the respective vaccine label) + 14 days, to minimize risk of confounding findings/observations.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
Combination Product: CD388 Injection · Drug: Saline placebo
Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
Combination Product: CD388 Injection · Drug: Saline placebo
Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
Combination Product: CD388 Injection · Drug: Saline placebo
Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
Combination Product: CD388 Injection · Drug: Saline placebo
Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
Combination Product: CD388 Injection · Drug: Saline placebo
Highest dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
Combination Product: CD388 Injection · Drug: Saline placebo
Highest dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
Combination Product: CD388 Injection · Drug: Saline placebo
CD388 liquid for injection
Sterile normal saline for injection
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388
Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)
Severity of TEAEs After a Single Dose of CD388
Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
Time frame: Day 1 through Day 120 (±14 days; Cohorts 1A/1B only); Day 1 through Day 374 (±14 days; Cohorts 2A/2B and 3A/3B); or Day 1 through Day 206 (±10 days; Cohort 4B only)
Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388
Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388
Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388
Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388
Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388
Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388
Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Apparent Clearance (CL/F) Following a Single Administration of CD388
Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Apparent Clearance (CL/F) Following a Single Administration of CD388
Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388
Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388
Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.
Time frame: Days 1 through 7, 9, 11, 14, 21, and 30 (all cohorts) and at outpatient visits: Days 45, 60, 90, and 120 (Cohorts 1A/1B only); Days 45, 84, 126, and 168 (Cohorts 2A/2B and 3A/3B); or Days 45, 84, 126, 168, and 206 (Cohort 4B only)
Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388
Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388
Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388
Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388
Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388
Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388
Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388
Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388
Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388
Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388
Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
Time frame: At inpatient visits on Days 206 (i.e., Dose 2 Day 1) through 212, 214, 216, 219, 226, and 236; and at outpatient visits: Days 251, 290, 332, and 374 (Cohorts 2A/2B and 3A/3B only)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Repeated Single Dose of CD388
Number of participants with at least one TEAE, including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.
Time frame: Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)
Severity of TEAEs After a Repeated Single Dose of CD388
Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.
Time frame: Day 207 through Day 412 (±10 days) (Cohorts 2A/2B and 3A/3B only)
A total of 77 participants were enrolled in the study at a single center, 33 of whom were randomized to receive study drug via intramuscular (IM) administration and 44 of whom were randomized to receive study drug via subcutaneous (SQ) administration.
| Milestone | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 12 |
| Completed | 8 | 6 | 5 | 5 | 8 | 8 | 4 | 8 | 10 |
| Not completed | 0 | 2 | 3 | 4 | 0 | 0 | 4 | 0 | 2 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 1 |
Number of participants with at least one TEAE, including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
| Participants | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|---|---|---|
| Participants with at least one TEAE | 5 | 5 | 5 | 8 | 5 | 4 | 5 | 3 | 7 |
| Participants with AEs leading to study withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to adverse events (AEs) and serious adverse events (SAEs) (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, electrocardiogram (ECG), and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a single dose of CD388.
| Participants | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|---|---|---|
| Mild | 5 | 5 | 2 | 5 | 4 | 4 | 3 | 3 | 6 |
| Moderate | 0 | 0 | 3 | 2 | 1 | 0 | 1 | 0 | 1 |
| Severe | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.
| micrograms/milliliter (ug/mL) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Peak Plasma Concentration (Cmax) Following a Single Administration of CD388 | 4.13 ± 0.747 | 10.4 ± 2.44 | 48.6 ± 11.7 | 3.57 ± 0.942 | 12.0 ± 3.35 | 32.7 ± 9.40 | 58.8 ± 17.5 |
Evaluation of the maximum plasma concentration (Cmax) following the first single dose of CD388 administered by either IM or SQ injection.
| micrograms/milliliter (ug/mL) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Peak Plasma Concentration (Cmax) Following a Single Administration of CD388 | 3.96 (2.91 to 5.34) | 10.4 (6.52 to 13.6) | 48.0 (35.2 to 67.7) | 3.72 (2.17 to 4.83) | 11.8 (6.84 to 17.0) | 31.6 (16.6 to 48.0) | 60.7 (34.3 to 91.3) |
Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.
| hours (h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388 | 111.08 ± 72.42 | 159.03 ± 83.10 | 85.64 ± 42.19 | 213.00 ± 108.43 | 137.48 ± 77.82 | 120.04 ± 67.83 | 109.54 ± 55.66 |
Evaluation of the time to maximum plasma concentration (Tmax) following the first single dose of CD388 administered by either IM or SQ injection.
| hours (h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Time to Maximum Plasma Concentration (Tmax) Following a Single Administration of CD388 | 96.07 (48.17 to 240.00) | 131.98 (71.97 to 312.00) | 78.31 (24.17 to 144.00) | 228.00 (72.00 to 312.02) | 131.28 (48.22 to 312.02) | 96.00 (48.17 to 240.00) | 96.00 (48.17 to 192.00) |
Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.
| hours (h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Terminal Elimination Half-life (t½) Following a Single Administration of CD388 | 1234.41 ± 140.04 | 1192.03 ± 235.80 | 1006.20 ± 314.39 | 1069.78 ± 216.48 | 1265.53 ± 223.93 | 1065.21 ± 239.19 | 1384.36 ± 282.53 |
Evaluation of the terminal elimination half-life (t½) following the first single dose of CD388 administered by either IM or SQ injection.
| hours (h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| MedianTerminal Elimination Half-life (t½) Following a Single Administration of CD388 | 1275.62 (985.09 to 1390.45) | 1285.85 (783.24 to 1471.71) | 1137.42 (540.88 to 1384.09) | 1052.39 (685.81 to 1350.50) | 1270.40 (796.65 to 1576.21) | 1040.30 (809.64 to 1502.38) | 1287.45 (1110.87 to 1998.04) |
Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.
| liters/hour (L/h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Apparent Clearance (CL/F) Following a Single Administration of CD388 | 0.00751 ± 0.00119 | 0.00867 ± 0.00177 | 0.00766 ± 0.00199 | 0.00900 ± 0.00230 | 0.00725 ± 0.00123 | 0.00883 ± 0.00213 | 0.00863 ± 0.00158 |
Evaluation of the apparent clearance (CL/F) following the first single dose of CD388 administered by either IM or SQ injection.
| liters/hour (L/h) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Apparent Clearance (CL/F) Following a Single Administration of CD388 | 0.00707 (0.00614 to 0.00991) | 0.00851 (0.00640 to 0.0112) | 0.00726 (0.00571 to 0.0116) | 0.00834 (0.00591 to 0.0128) | 0.00717 (0.00551 to 0.00909) | 0.00912 (0.00493 to 0.0115) | 0.00870 (0.00648 to 0.0111) |
Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.
| liters (L) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388 | 13.3 ± 1.91 | 14.8 ± 4.40 | 10.7 ± 2.99 | 13.4 ± 2.59 | 13.3 ± 3.70 | 13.1 ± 2.61 | 17.1 ± 3.76 |
Evaluation of the apparent volume of distribution (V\[z\]/F) following the first single dose of CD388 administered by either IM or SQ injection.
| liters (L) | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Apparent Volume of Distribution (V[z]/F) Following a Single Administration of CD388 | 13.9 (10.3 to 15.8) | 14.4 (11.1 to 23.9) | 10.9 (6.47 to 15.1) | 12.2 (11.4 to 18.7) | 12.7 (9.27 to 20.7) | 12.9 (10.7 to 18.9) | 16.7 (11.2 to 24.2) |
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.
| ug*h/mL | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388 | 5450 ± 728 | 15000 ± 4320 | 53800 ± 12000 | 4830 ± 965 | 18800 ± 3360 | 49000 ± 13100 | 96300 ± 16700 |
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following the first single dose of CD388 administered by either IM or SQ injection.
| ug*h/mL | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Single Administration of CD388 | 5460 (4410 to 6530) | 15100 (7250 to 21100) | 52100 (37600 to 71200) | 4960 (3270 to 6300) | 18700 (13700 to 24400) | 46500 (34800 to 76600) | 94700 (71700 to 121000) |
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.
| ug*h/mL | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388 | 6790 ± 973 | 17900 ± 3670 | 61800 ± 13600 | 5870 ± 1470 | 21200 ± 3670 | 54400 ± 16900 | 107000 ± 19700 |
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following the first single dose of CD388 administered by either IM or SQ injection.
| ug*h/mL | Cohort 1A CD388 50 mg IM | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 1B CD388 50 mg SQ | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ | Cohort 4B CD388 900 mg SQ |
|---|---|---|---|---|---|---|---|
| Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Single Administration of CD388 | 7080 (5050 to 8140) | 17600 (13300 to 23400) | 62100 (38800 to 78800) | 6000 (3920 to 8470) | 21000 (16500 to 27200) | 49300 (39100 to 91400) | 103000 (80800 to 139000) |
Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| micrograms/milliliter (ug/mL) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388 | 10.5 ± 3.30 | 28.8 ± 7.66 | 13.0 ± 5.34 | 31.1 ± 7.86 |
Evaluation of the maximum plasma concentration (Cmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| micrograms/milliliter (ug/mL) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Peak Plasma Concentration (Cmax) Following a Repeated Single Administration of CD388 | 9.94 (6.68 to 14.4) | 29.8 (18.0 to 38.3) | 12.5 (6.84 to 22.0) | 29.3 (23.8 to 43.8) |
Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| hours (h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388 | 104.02 ± 81.25 | 161.14 ± 75.53 | 251.99 ± 200.79 | 105.02 ± 49.89 |
Evaluation of the time to maximum plasma concentration (Tmax) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| hours (h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Time to Maximum Plasma Concentration (Tmax) Following a Repeated Single Administration of CD388 | 84.00 (48.00 to 264.00) | 144.00 (48.00 to 264.00) | 227.99 (48.00 to 695.97) | 96.00 (47.07 to 167.00) |
Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| hours (h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388 | 1324.07 ± 198.33 | 1408.43 ± 336.72 | 1059.55 ± 409.51 | 1301.42 ± 83.00 |
Evaluation of the terminal elimination half-life (t½) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| hours (h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Terminal Elimination Half-life (t½) Following a Repeated Single Administration of CD388 | 1342.81 (1108.91 to 1639.43) | 1506.38 (670.64 to 1721.28) | 1218.60 (508.57 to 1539.09) | 1348.40 (1175.81 to 1371.62) |
Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| liters/hour (L/h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388 | 0.00923 ± 0.00123 | 0.00886 ± 0.00170 | 0.00802 ± 0.00218 | 0.00897 ± 0.00210 |
Evaluation of the apparent clearance (CL/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| liters/hour (L/h) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Apparent Clearance (CL/F) Following a Repeated Single Administration of CD388 | 0.00954 (0.00706 to 0.0104) | 0.00918 (0.00642 to 0.0105) | 0.00866 (0.00507 to 0.0116) | 0.00946 (0.00534 to 0.0106) |
Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| liters (L) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388 | 17.4 ± 1.85 | 17.8 ± 5.45 | 11.7 ± 4.70 | 16.7 ± 3.55 |
Evaluation of the apparent volume of distribution (V\[z\]/F) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| liters (L) | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Apparent Volume of Distribution (V[z]/F) Following a Repeated Single Administration of CD388 | 16.6 (15.4 to 20.2) | 16.7 (10.1 to 26.0) | 9.46 (7.45 to 19.2) | 18.3 (10.4 to 18.5) |
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| ug*h/mL | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388 | 14400 ± 2050 | 41300 ± 15400 | 18000 ± 5090 | 41100 ± 21100 |
Evaluation of the area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC\[0-t\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| ug*h/mL | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Sample (AUC[0-t]) Following a Repeated Single Administration of CD388 | 13600 (12800 to 18000) | 41800 (13400 to 60600) | 16000 (12900 to 26600) | 39100 (13400 to 72700) |
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| ug*h/mL | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Mean Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388 | 16500 ± 2530 | 52600 ± 10800 | 20000 ± 5830 | 53400 ± 17400 |
Evaluation of the area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC\[0-∞\]) following a repeated single dose of CD388 administered by either IM or SQ injection (after washout of 5 effective half-lives from the first dose).
| ug*h/mL | Cohort 2A CD388 150 mg IM | Cohort 3A CD388 450 mg IM | Cohort 2B CD388 150 mg SQ | Cohort 3B CD388 450 mg SQ |
|---|---|---|---|---|
| Median Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞]) Following a Repeated Single Administration of CD388 | 15700 (14500 to 21200) | 49000 (42900 to 70100) | 17300 (12900 to 29600) | 47600 (42300 to 84300) |
Number of participants with at least one TEAE, including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.
| Participants | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 150 mg SQ | CD388 450 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|
| Participants with at least one TEAE | 2 | 4 | 2 | 2 | 3 | 1 |
| Participants with AEs leading to study withdrawal | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum severity of TEAEs reported (in participants with at least one TEAE), including but not limited to AEs and SAEs (including systemic reactogenicity/injection site reactions and hypersensitivity reactions), and AEs leading to study drug discontinuation and/or study withdrawal, based on vital signs, 12-lead ECG, and clinical laboratory test (including hematology, coagulation, serum chemistry, and urinalysis) abnormalities following a repeated single dose of CD388.
| Participants | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 150 mg SQ | CD388 450 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|
| Mild | 2 | 2 | 2 | 2 | 3 | 1 |
| Moderate | 0 | 2 | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Adverse events were collected for all participants from the time of signing the informed consent form through the final study visit (Day 120 for the 50 mg dose arm [Cohorts 1A/1B]; Day 412 for the 150 mg and 450 mg dose arms [Cohorts 2A/2B and 3A/3B]; and Day 206 for the 900 mg dose arm [Cohort 4B]).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD388 50 mg IM | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| CD388 150 mg IM | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| CD388 450 mg IM | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Pooled Placebo IM | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| CD388 50 mg SQ | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| CD388 150 mg SQ | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| CD388 450 mg SQ | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| CD388 900 mg SQ | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Pooled Placebo SQ | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/8 | 2/8 | 2/8 | 4/9 | 5/8 | 0/8 | 2/8 | 0/8 | 2/12 |
| Viral infectionInfections and infestations | 0/8 | 1/8 | 3/8 | 1/9 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| COVID-19Infections and infestations | 1/8 | 2/8 | 1/8 | 2/9 | 0/8 | 1/8 | 0/8 | 0/8 | 0/12 |
| PresyncopeNervous system disorders | 0/8 | 0/8 | 0/8 | 0/9 | 0/8 | 2/8 | 0/8 | 0/8 | 1/12 |
| Injection site painGeneral disorders | 0/8 | 0/8 | 1/8 | 2/9 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 0/8 | 2/9 | 0/8 | 1/8 | 1/8 | 0/8 | 0/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 0/8 | 2/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/12 |
| DizzinessNervous system disorders | 0/8 | 0/8 | 0/8 | 1/9 | 0/8 | 0/8 | 0/8 | 0/8 | 2/12 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 | 1/8 | 1/9 | 0/8 | 0/8 | 0/8 | 0/8 | 1/12 |
| VomitingGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 0/9 | 1/8 | 0/8 | 0/8 | 0/8 | 1/12 |
The Safety Population included all randomized participants who received any amount of study drug (77 total; 33 \[IM route\], 44 \[SQ route\]).
| Age, Continuous(years) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 38.9 ± 7.77 | 41.1 ± 12.83 | 38.6 ± 12.73 | 39.0 ± 15.51 | 42.8 ± 12.58 | 32.8 ± 10.75 | 39.3 ± 14.95 | 41.9 ± 13.97 | 39.4 ± 13.82 | 39.3 ± 12.62 |
| Age, Continuous(years) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 37.0 (30 to 55) | 38.5 (24 to 57) | 32.5 (28 to 63) | 30.0 (23 to 65) | 45.5 (21 to 56) | 30.5 (22 to 50) | 35.5 (19 to 62) | 34.0 (29 to 65) | 37.5 (18 to 59) | 35.0 (18 to 65) |
| Sex: Female, Male(Participants) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 1 | 5 | 3 | 1 | 2 | 1 | 5 | 23 |
| Male | 7 | 4 | 7 | 4 | 5 | 7 | 6 | 7 | 7 | 54 |
| Ethnicity (NIH/OMB)(Participants) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 6 |
| Not Hispanic or Latino | 8 | 5 | 7 | 9 | 8 | 7 | 7 | 8 | 12 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 3 | 4 | 4 | 6 | 5 | 7 | 8 | 43 |
| White | 5 | 4 | 4 | 3 | 4 | 2 | 3 | 1 | 4 | 30 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Weight(kilograms (kg)) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 86.19 ± 5.680 | 79.53 ± 11.945 | 79.51 ± 16.157 | 79.97 ± 12.596 | 83.15 ± 19.835 | 81.03 ± 17.053 | 85.28 ± 16.085 | 86.30 ± 10.079 | 76.73 ± 13.775 | 81.67 ± 13.847 |
| Weight(kg) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 85.50 (77.6 to 95.3) | 80.40 (64.8 to 99.9) | 75.60 (63.0 to 105.9) | 80.90 (55.0 to 95.2) | 78.75 (59.9 to 112.5) | 78.20 (59.5 to 115.8) | 83.75 (64.1 to 118.6) | 87.90 (68.5 to 99.9) | 79.50 (55.4 to 101.7) | 81.70 (55.0 to 118.6) |
| Height(centimeters) | CD388 50 mg IM | CD388 150 mg IM | CD388 450 mg IM | Pooled Placebo IM | CD388 50 mg SQ | CD388 150 mg SQ | CD388 450 mg SQ | CD388 900 mg SQ | Pooled Placebo SQ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 178.88 ± 8.919 | 172.25 ± 11.498 | 174.50 ± 6.655 | 172.00 ± 10.283 | 173.38 ± 11.975 | 172.38 ± 10.993 | 172.00 ± 11.514 | 176.19 ± 7.348 | 171.17 ± 7.884 | 173.49 ± 9.529 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Oct 2023, 19 months.
Results were first posted in Jan 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.